Silo Pharma shares are trading higher after the company obtained an exclusive global license to develop, manufacture, and commercialize its Alzheimer's drug.
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma shares are trading higher after the company obtained an exclusive global license to develop, manufacture, and commercialize its Alzheimer's drug.
July 16, 2024 | 10:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma shares are trading higher after the company obtained an exclusive global license to develop, manufacture, and commercialize its Alzheimer's drug.
The exclusive global license for the Alzheimer's drug is a significant milestone for Silo Pharma, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100